151 related articles for article (PubMed ID: 37894699)
1. An Ultrafast UPLC-MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib.
Attwa MW; Bakheit AH; Abdelhameed AS; Kadi AA
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894699
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Alectinib Metabolic Stability in HLMs Using Fast LC-MS/MS Method: In Silico ADME Profile, P450 Metabolic Lability, and Toxic Alerts Screening.
Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896209
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes.
Attwa MW; AlRabiah H; Kadi AA
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903615
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies.
Attwa MW; Kadi AA; Abdelhameed AS; Alhazmi HA
Drug Des Devel Ther; 2020; 14():783-793. PubMed ID: 32158196
[TBL] [Abstract][Full Text] [Related]
5. Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method.
Attwa MW; AlRabiah H; Mostafa GAE; Bakheit AH; Kadi AA
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985590
[TBL] [Abstract][Full Text] [Related]
6. LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes.
Mostafa GAE; Kadi AA; AlMasoud N; Attwa MW; Al-Shakliah NS; AlRabiah H
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122806. PubMed ID: 34325312
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation.
Attwa MW; Abdelhameed AS; Kadi AA
Drug Des Devel Ther; 2021; 15():3915-3925. PubMed ID: 34552321
[TBL] [Abstract][Full Text] [Related]
8. Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance.
Tang LWT; Chan ECY
J Pharm Biomed Anal; 2022 May; 214():114731. PubMed ID: 35325798
[TBL] [Abstract][Full Text] [Related]
9. Estimation of zorifertinib metabolic stability in human liver microsomes using LC-MS/MS.
Attwa MW; Al-Shakliah NS; AlRabiah H; Kadi AA; Abdelhameed AS
J Pharm Biomed Anal; 2022 Mar; 211():114626. PubMed ID: 35123331
[TBL] [Abstract][Full Text] [Related]
10. Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation.
Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903565
[TBL] [Abstract][Full Text] [Related]
11. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Jiang Z; Shi L; Zhang Y; Lin G; Wang Y
J Pharm Biomed Anal; 2020 Nov; 191():113613. PubMed ID: 32971496
[TBL] [Abstract][Full Text] [Related]
13. LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay.
Attwa MW; Abdelhameed AS; Al-Shakliah NS; Kadi AA
Drug Des Devel Ther; 2020; 14():4439-4449. PubMed ID: 33122888
[TBL] [Abstract][Full Text] [Related]
14. Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.
Surendran S; Paul D; Pokharkar S; Choulwar S; Deshpande A; Giri S; Satheeshkumar N
J Pharm Biomed Anal; 2019 Feb; 164():509-513. PubMed ID: 30453157
[TBL] [Abstract][Full Text] [Related]
15. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
16. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry.
Attwa MW; Kadi AA; Darwish HW
Drug Des Devel Ther; 2020; 14():111-119. PubMed ID: 32021096
[TBL] [Abstract][Full Text] [Related]
18. Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS.
Attwa MW; Darwish HW; Alhazmi HA; Kadi AA
Clin Chim Acta; 2018 Oct; 485():298-304. PubMed ID: 30006284
[TBL] [Abstract][Full Text] [Related]
19. An update on acalabrutinib to treat chronic lymphocytic leukemia.
Blackmon A; O'Brien S
Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
[TBL] [Abstract][Full Text] [Related]
20. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]